Quincey James 4

What Happened
Quincey James, a director of Pfizer Inc., was granted 7,686.539 units (phantom shares) on 2026-04-23 at an attributed value of $26.67 per unit, totaling $205,000. This was an award of deferred director compensation (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-27 (filed within the normal reporting window).
• Units granted: 7,686.539 phantom-share units; attributed price: $26.67; total value reported: $205,000.
• Shares owned after transaction: not reported in this filing.
• Plan: Granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Footnotes: (1) Each unit = one phantom share of common stock. (2) Units represent deferred director compensation. (3) Units are settled in cash or common stock at the director’s election following the director’s retirement from the board.

Context
These units are derivative, deferred compensation—meaning they track Pfizer’s stock value but are not immediately issued common shares. They will be settled in cash or stock later (typically upon retirement), so this grant is routine director compensation rather than an immediate market bet.